Screening for Unhealthy Drug Use US Preventive Services Task Force Recommendation Statement

被引:158
作者
Krist, Alex H. [1 ,2 ]
Davidson, Karina W. [3 ]
Mangione, Carol M. [4 ]
Barry, Michael J. [5 ]
Cabana, Michael [6 ]
Caughey, Aaron B. [7 ]
Curry, Susan J. [8 ]
Donahue, Katrina [9 ]
Doubeni, Chyke A. [10 ]
Epling, John W., Jr. [11 ]
Kubik, Martha [12 ]
Ogedegbe, Gbenga [13 ]
Pbert, Lori [14 ]
Silverstein, Michael [15 ]
Simon, Melissa A. [16 ]
Tseng, Chien-Wen [17 ,18 ]
Wong, John B. [19 ]
机构
[1] Virginia Commonwealth Univ, 830 E Main St,One Capitol Sq,Sixth Floor, Richmond, VA 23219 USA
[2] Fairfax Family Practice Residency, Fairfax, VA USA
[3] Northwell Hlth, Feinstein Inst Med Res, Manhasset, NY USA
[4] Univ Calif Los Angeles, Los Angeles, CA USA
[5] Harvard Med Sch, Boston, MA 02115 USA
[6] Univ Calif San Francisco, San Francisco, CA 94143 USA
[7] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[8] Univ Iowa, Iowa City, IA USA
[9] Univ N Carolina, Chapel Hill, NC 27515 USA
[10] Mayo Clin, Rochester, MN USA
[11] Virginia Tech, Carilion Sch Med, Roanoke, VA USA
[12] Temple Univ, Philadelphia, PA 19122 USA
[13] NYU, New York, NY USA
[14] Univ Massachusetts, Sch Med, Worcester, MA USA
[15] Boston Univ, Boston, MA 02215 USA
[16] Northwestern Univ, Evanston, IL USA
[17] Univ Hawaii, Honolulu, HI 96822 USA
[18] Pacific Hlth Res & Educ Inst, Honolulu, HI USA
[19] Tufts Univ, Sch Med, Boston, MA 02111 USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2020年 / 323卷 / 22期
关键词
SUBSTANCE USE; ADOLESCENTS; ADULTS; PHARMACOTHERAPY; INTERVENTIONS; CHILDREN; RISK;
D O I
10.1001/jama.2020.8020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Importance An estimated 12% of adults 18 years or older and 8% of adolescents aged 12 to 17 years report unhealthy use of prescription or illegal drugs in the US. Objective To update its 2008 recommendation, the USPSTF commissioned reviews of the evidence on screening by asking questions about drug use and interventions for unhealthy drug use in adults and adolescents. Population This recommendation statement applies to adults 18 years or older, including pregnant and postpartum persons, and adolescents aged 12 to 17 years in primary care settings. This statement does not apply to adolescents or adults who have a currently diagnosed drug use disorder or are currently undergoing or have been referred for drug use treatment. This statement applies to settings and populations for which services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. Evidence Assessment In adults, the USPSTF concludes with moderate certainty that screening by asking questions about unhealthy drug use has moderate net benefit when services for accurate diagnosis of unhealthy drug use or drug use disorders, effective treatment, and appropriate care can be offered or referred. In adolescents, because of the lack of evidence, the USPSTF concludes that the benefits and harms of screening for unhealthy drug use are uncertain and that the balance of benefits and harms cannot be determined. Recommendation The USPSTF recommends screening by asking questions about unhealthy drug use in adults 18 years or older. Screening should be implemented when services for accurate diagnosis, effective treatment, and appropriate care can be offered or referred. (Screening refers to asking questions about unhealthy drug use, not testing biological specimens.) (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for unhealthy drug use in adolescents. (I statement) This 2020 US Preventive Services Task Force Recommendation Statement recommends screening for unhealthy drug use in adults 18 years or older when services for diagnosis, treatment, and care can be offered or referred (B recommendation) and concludes that evidence is insufficient to assess the balance of benefits and harms of screening for unhealthy drug use in adolescents (I statement).
引用
收藏
页码:2301 / 2309
页数:9
相关论文
共 49 条
  • [1] American Academy of Pediatrics, SUBST US SCREEN INT
  • [2] [Anonymous], 2019, Obstet Gynecol, V133, pe78, DOI 10.1097/AOG.0000000000003013
  • [3] [Anonymous], 2011, Obstet Gynecol, V117, P200, DOI 10.1097/AOG.0b013e31820a6216
  • [4] [Anonymous], 2011, Obstet Gynecol, V117, P751, DOI 10.1097/AOG.0b013e318214784e
  • [5] [Anonymous], 2019, Obstet Gynecol, V133, P51, DOI [10.1097/AOG.0000000000003025, DOI 10.1097/AOG.0000000000003025]
  • [6] [Anonymous], 2018, PRINC DRUG ADD TREAT
  • [7] [Anonymous], 2016, PREV PRESCR DRUG MIS
  • [8] [Anonymous], 2014, DRUGS BRAINS BEH SCI
  • [9] [Anonymous], 2017, TREAT OP US DIS DUR
  • [10] [Anonymous], 2018, MED TREAT OP DIS